Hadi, T. (2026). Evaluation of IL-17 as an Inflammatory Marker in Patients with Hypothyroidism and Low Vitamin D Levels. , 4(2), 84-94. doi: 10.66723/zjhms.2026.171680.1147
Teeba Fares Hadi. "Evaluation of IL-17 as an Inflammatory Marker in Patients with Hypothyroidism and Low Vitamin D Levels". , 4, 2, 2026, 84-94. doi: 10.66723/zjhms.2026.171680.1147
Hadi, T. (2026). 'Evaluation of IL-17 as an Inflammatory Marker in Patients with Hypothyroidism and Low Vitamin D Levels', , 4(2), pp. 84-94. doi: 10.66723/zjhms.2026.171680.1147
Hadi, T. Evaluation of IL-17 as an Inflammatory Marker in Patients with Hypothyroidism and Low Vitamin D Levels. , 2026; 4(2): 84-94. doi: 10.66723/zjhms.2026.171680.1147
Evaluation of IL-17 as an Inflammatory Marker in Patients with Hypothyroidism and Low Vitamin D Levels
Institute of Genetic Engineering and Biotechnology for postgraduate studies, University of Baghdad, Baghdad, Iraq
Abstract
Hypothyroidism is defined as the inability of the thyroid gland to produce sufficient hormones Interleukin-17 (IL-17) plays a crucial role in the development of hypothyroidism by promoting inflammation and modulating immune responses. This study aimed to evaluate the concentration of certain cytokines, including IL-17, and the low serum vitamin D levels in Iraqis with hypothyroidism. The study included 65 male and female participants (58.4% female and 41.5% male) aged 25–57 years, as well as 30 healthy individuals of varying ages. After a 12–14 hour fast, blood samples were collected to assess serum IL-17 levels using an ELISA assay. The results revealed an increased concentration of interleukin-17 in patients (13.53 ± 3.05) compared to the control group (10.31 ± 1.06). Vitamin D levels were also significantly decreased in patients (15.4 ± 2.15), suggesting that vitamin D deficiency may contribute to the elevated interleukin-17 levels, as pro-inflammatory cytokines are believed to play a role in the mechanism of hypothyroidism. The results also showed a significant increase in FT3, FT4levels, with a mean serum FT3 level of 4.12 ± 0.31 pmol/L in patients and 3.21 ± 1.05 pmol/L in healthy individuals. While mean serum free thyroid hormone (FT4) level in patients was 3.61 ± 1.17 pmol/L, compared with 2.06 ± 2.42 pmol/L in healthy individuals. A significant increase in thyroid-stimulating hormone (TSH) concentration were also observed., while the mean thyroid-stimulating hormone (TSH) level in patients was 9.20 ± 0.30 mIU/L, compared with 0.42 ± 0.56 mIU/L in healthy individuals.